10 Best Dividend Growth Stocks Insiders Are Buying for January 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
In the current market environment, investors seek undervalued stocks with strong fundamentals amid volatility in technology, healthcare, and consumer sectors. This stock watchlist features 10 high-quality picks selected using ValueSense's proprietary screening methodology, focusing on Quality rating, intrinsic value comparisons, robust Free Cash Flow (FCF) generation, and attractive ROIC metrics. Stocks were filtered for large-cap stability (market caps from $74.7B to $1,647.0B), positive revenue trends where possible, and high gross margins indicating competitive moats. ValueSense data highlights opportunities where intrinsic value suggests potential upside, making these top stocks to buy now for diversified investment ideas in best value stocks.
Featured Stock Analysis
Stock #1: Broadcom Inc. (AVGO)
| Metric | Value |
|---|---|
| Market Cap | $1,647.0B |
| Quality Rating | 8.2 |
| Intrinsic Value | $128.4 |
| 1Y Return | 49.8% |
| Revenue | $63.9B |
| Free Cash Flow | $26.9B |
| Revenue Growth | 23.9% |
| FCF margin | 42.1% |
| Gross margin | 67.8% |
| ROIC | 18.3% |
| Total Debt to Equity | 80.1% |
Investment Thesis
Broadcom Inc. (AVGO) stands out as a technology leader with a Quality rating of 8.2, the highest in this watchlist, backed by exceptional financials including $63.9B in revenue and $26.9B in Free Cash Flow. Its FCF margin of 42.1% and gross margin of 67.8% reflect pricing power in semiconductors and infrastructure software. Despite a massive $1,647.0B market cap, the intrinsic value of $128.4 indicates room for appreciation based on ValueSense calculations, supported by 23.9% revenue growth and 18.3% ROIC. The stock's 49.8% 1Y Return underscores momentum, positioning AVGO as a core holding for growth-oriented value analysis.
Key Catalysts
- Strong 23.9% revenue growth driving scalable profitability
- Industry-leading 42.1% FCF margin for reinvestment and shareholder returns
- High 67.8% gross margin signaling durable competitive advantages
- 18.3% ROIC demonstrating efficient capital allocation
Risk Factors
- Elevated 80.1% Total Debt to Equity requiring careful leverage monitoring
- Dependence on tech sector cycles and supply chain dynamics
- High market cap may limit short-term upside volatility
Stock #2: Johnson & Johnson (JNJ)
| Metric | Value |
|---|---|
| Market Cap | $502.2B |
| Quality Rating | 6.3 |
| Intrinsic Value | $196.8 |
| 1Y Return | 45.1% |
| Revenue | $92.1B |
| Free Cash Flow | $19.1B |
| Revenue Growth | 5.1% |
| FCF margin | 20.7% |
| Gross margin | 68.1% |
| ROIC | 11.2% |
| Total Debt to Equity | 8.1% |
Investment Thesis
Johnson & Johnson (JNJ), a healthcare stalwart, offers stability with a $502.2B market cap, Quality rating of 6.3, and intrinsic value of $196.8 suggesting significant undervaluation potential. Generating $92.1B in revenue and $19.1B FCF, JNJ maintains a healthy 20.7% FCF margin and 68.1% gross margin, with 5.1% revenue growth and 11.2% ROIC. Its impressive 45.1% 1Y Return highlights resilience, making it a defensive pick in healthcare stock picks for balanced portfolios.
Key Catalysts
- Steady 5.1% revenue growth in diversified pharma and medtech segments
- Robust 68.1% gross margin supporting R&D innovation
- Low 8.1% Total Debt to Equity for financial flexibility
- Proven 45.1% 1Y Return amid market uncertainty
Risk Factors
- Patent cliffs and regulatory hurdles in pharmaceuticals
- Moderate 11.2% ROIC compared to high-growth peers
- Healthcare policy changes impacting margins
Stock #3: The Coca-Cola Company (KO)
| Metric | Value |
|---|---|
| Market Cap | $298.3B |
| Quality Rating | 6.7 |
| Intrinsic Value | $42.5 |
| 1Y Return | 11.8% |
| Revenue | $47.7B |
| Free Cash Flow | $5,570.0M |
| Revenue Growth | 2.8% |
| FCF margin | 11.7% |
| Gross margin | 61.6% |
| ROIC | 33.7% |
| Total Debt to Equity | 142.5% |
Investment Thesis
The Coca-Cola Company (KO) exemplifies consumer staples reliability with a $298.3B market cap, 6.7 Quality rating, and $42.5 intrinsic value pointing to value opportunities. Key metrics include $47.7B revenue, $5,570.0M FCF (11.7% margin), 61.6% gross margin, and standout 33.7% ROIC, despite modest 2.8% revenue growth and 11.8% 1Y Return. High ROIC underscores brand strength, ideal for undervalued stocks to buy in stable sectors.
Key Catalysts
- Exceptional 33.7% ROIC from iconic brand moat
- Consistent 61.6% gross margin enabling dividend sustainability
- 2.8% revenue growth in essential beverages
- Defensive positioning for economic downturns
Risk Factors
- High 142.5% Total Debt to Equity straining balance sheet
- Slow 2.8% revenue growth vulnerable to consumer shifts
- Commodity price fluctuations affecting costs
Stock #4: Pfizer Inc. (PFE)
| Metric | Value |
|---|---|
| Market Cap | $143.1B |
| Quality Rating | 6.1 |
| Intrinsic Value | $45.9 |
| 1Y Return | -3.8% |
| Revenue | $62.8B |
| Free Cash Flow | $10.4B |
| Revenue Growth | 4.4% |
| FCF margin | 16.5% |
| Gross margin | 69.4% |
| ROIC | 9.8% |
| Total Debt to Equity | 66.3% |
Investment Thesis
Pfizer Inc. (PFE) provides healthcare exposure at a $143.1B market cap with a 6.1 Quality rating and $45.9 intrinsic value, highlighting undervaluation. Financials show $62.8B revenue, $10.4B FCF (16.5% margin), 69.4% gross margin, 4.4% revenue growth, 9.8% ROIC, and 66.3% Total Debt to Equity. Despite a -3.8% 1Y Return, pipeline potential offers rebound analysis in stock picks.
Key Catalysts
- Solid 69.4% gross margin from blockbuster drugs
- 4.4% revenue growth post-COVID diversification
- Strong $10.4B FCF for acquisitions and dividends
- Attractive intrinsic value for long-term recovery
Risk Factors
- Recent -3.8% 1Y Return signaling pipeline risks
- 66.3% debt levels amid R&D spend
- Patent expirations pressuring revenue
Stock #5: Lowe's Companies, Inc. (LOW)
| Metric | Value |
|---|---|
| Market Cap | $136.9B |
| Quality Rating | 5.5 |
| Intrinsic Value | $153.0 |
| 1Y Return | 0.4% |
| Revenue | $84.3B |
| Free Cash Flow | $7,050.0M |
| Revenue Growth | 0.6% |
| FCF margin | 8.4% |
| Gross margin | 32.0% |
| ROIC | 22.7% |
| Total Debt to Equity | (69.3%) |
Investment Thesis
Lowe's Companies, Inc. (LOW) in the consumer discretionary sector boasts a $136.9B market cap, 5.5 Quality rating, and $153.0 intrinsic value. Metrics feature $84.3B revenue, $7,050.0M FCF (8.4% margin), 32.0% gross margin, 22.7% ROIC, and 69.3% Total Debt to Equity indicating net cash position. Flat 0.6% revenue growth and 0.4% 1Y Return suggest cyclical value play.
Key Catalysts
- High 22.7% ROIC in home improvement demand
- Net cash position (69.3% debt/equity) for buybacks
- Large $84.3B revenue base for stability
- Housing market recovery potential
Risk Factors
- Minimal 0.6% revenue growth tied to housing slowdown
- Cyclical exposure to economic conditions
- Lower 5.5 Quality rating vs. peers
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #6: Starbucks Corporation (SBUX)
| Metric | Value |
|---|---|
| Market Cap | $96.1B |
| Quality Rating | 6.3 |
| Intrinsic Value | $50.3 |
| 1Y Return | -8.4% |
| Revenue | $37.2B |
| Free Cash Flow | $2,442.0M |
| Revenue Growth | 2.8% |
| FCF margin | 6.6% |
| Gross margin | 34.4% |
| ROIC | 9.8% |
| Total Debt to Equity | (329.0%) |
Investment Thesis
Starbucks Corporation (SBUX) offers consumer staples growth at $96.1B market cap, 6.3 Quality rating, and $50.3 intrinsic value. Data includes $37.2B revenue, $2,442.0M FCF (6.6% margin), 34.4% gross margin, 9.8% ROIC, and 329.0% Total Debt to Equity (net cash). 2.8% revenue growth offsets -8.4% 1Y Return, positioning for turnaround.
Key Catalysts
- Global brand driving 2.8% revenue expansion
- Net cash flexibility for international growth
- Improving 34.4% gross margin trends
- Loyalty program fueling repeat business
Risk Factors
- -8.4% 1Y Return from competitive pressures
- Low 6.6% FCF margin indicating efficiency needs
- Consumer spending sensitivity
Stock #7: NIKE, Inc. (NKE)
| Metric | Value |
|---|---|
| Market Cap | $93.5B |
| Quality Rating | 5.2 |
| Intrinsic Value | $46.1 |
| 1Y Return | -13.7% |
| Revenue | $46.5B |
| Free Cash Flow | $2,475.0M |
| Revenue Growth | (5.0%) |
| FCF margin | 5.3% |
| Gross margin | 41.0% |
| ROIC | 13.8% |
| Total Debt to Equity | 80.1% |
Investment Thesis
NIKE, Inc. (NKE) in apparel shows $93.5B market cap, 5.2 Quality rating, $46.1 intrinsic value. Highlights: $46.5B revenue, $2,475.0M FCF (5.3% margin), 41.0% gross margin, 13.8% ROIC, 80.1% debt/equity, -5.0% revenue growth, -13.7% 1Y Return. Brand strength supports recovery analysis.
Key Catalysts
- 41.0% gross margin from premium pricing
- 13.8% ROIC in direct-to-consumer shift
- Iconic brand for long-term innovation
- Digital sales growth potential
Risk Factors
- Declining -5.0% revenue growth
- -13.7% 1Y Return amid competition
- Inventory and China market risks
Stock #8: Elevance Health Inc. (ELV)
| Metric | Value |
|---|---|
| Market Cap | $80.2B |
| Quality Rating | 6.1 |
| Intrinsic Value | $635.8 |
| 1Y Return | -2.8% |
| Revenue | $194.8B |
| Free Cash Flow | $3,767.0M |
| Revenue Growth | 12.0% |
| FCF margin | 1.9% |
| Gross margin | 77.7% |
| ROIC | 12.0% |
| Total Debt to Equity | 2.1% |
Investment Thesis
Elevance Health Inc. (ELV) in healthcare has $80.2B market cap, 6.1 Quality rating, standout $635.8 intrinsic value. Metrics: $194.8B revenue, $3,767.0M FCF (1.9% margin), 77.7% gross margin, 12.0% ROIC, 2.1% debt/equity, 12.0% revenue growth, -2.8% 1Y Return.
Key Catalysts
- Rapid 12.0% revenue growth in managed care
- Ultra-low 2.1% debt for stability
- 77.7% gross margin leadership
- Scale from massive revenue base
Risk Factors
- Thin 1.9% FCF margin pressuring cash flows
- Regulatory risks in health insurance
- Recent -2.8% 1Y Return
Stock #9: TransDigm Group Incorporated (TDG)
| Metric | Value |
|---|---|
| Market Cap | $78.6B |
| Quality Rating | 6.7 |
| Intrinsic Value | $1,127.3 |
| 1Y Return | 8.3% |
| Revenue | $8,831.0M |
| Free Cash Flow | $1,816.0M |
| Revenue Growth | 11.2% |
| FCF margin | 20.6% |
| Gross margin | 59.3% |
| ROIC | 19.1% |
| Total Debt to Equity | (310.3%) |
Investment Thesis
TransDigm Group Incorporated (TDG) in industrials features $78.6B market cap, 6.7 Quality rating, $1,127.3 intrinsic value. Includes $8,831.0M revenue, $1,816.0M FCF (20.6% margin), 59.3% gross margin, 19.1% ROIC, 310.3% debt/equity (net cash), 11.2% revenue growth, 8.3% 1Y Return.
Key Catalysts
- 11.2% revenue growth in aerospace aftermarket
- Strong 20.6% FCF margin
- 19.1% ROIC from acquisitions
- Net cash position enabling expansion
Risk Factors
- Aerospace cycle dependence
- Acquisition-driven growth risks
- High historical leverage patterns
Stock #10: Cintas Corporation (CTAS)
| Metric | Value |
|---|---|
| Market Cap | $74.7B |
| Quality Rating | 6.5 |
| Intrinsic Value | $74.7 |
| 1Y Return | 1.7% |
| Revenue | $10.8B |
| Free Cash Flow | $1,780.7M |
| Revenue Growth | 8.6% |
| FCF margin | 16.5% |
| Gross margin | 11.8% |
| ROIC | 29.3% |
| Total Debt to Equity | 14.1% |
Investment Thesis
Cintas Corporation (CTAS) rounds out the list with $74.7B market cap, 6.5 Quality rating, $74.7 intrinsic value. Data: $10.8B revenue, $1,780.7M FCF (16.5% margin), 11.8% gross margin, elite 29.3% ROIC, 14.1% debt/equity, 8.6% revenue growth, 1.7% 1Y Return. Uniform services moat shines.
Key Catalysts
- Top-tier 29.3% ROIC in essential services
- 8.6% revenue growth trajectory
- Healthy 16.5% FCF margin
- Recurring revenue stability
Risk Factors
- Lower 11.8% gross margin vs. peers
- Competition in business services
- Modest 1.7% 1Y Return
Portfolio Diversification Insights
This stock watchlist balances sectors: technology (AVGO), healthcare (JNJ, PFE, ELV), consumer staples (KO, SBUX), discretionary (LOW, NKE), industrials (TDG), and services (CTAS). High-quality leaders like AVGO (8.2 rating) complement defensives like JNJ and KO (high ROIC). Allocation suggestion: 20% tech, 30% healthcare, 20% staples, 30% cyclicals for reduced volatility. Cross-references show healthcare's low debt (e.g., JNJ 8.1%, ELV 2.1%) offsetting industrials' net cash positions, enhancing overall portfolio diversification.
Market Timing & Entry Strategies
Consider entry on pullbacks to intrinsic value levels, such as AVGO near $128.4 or ELV toward $635.8, using ValueSense charting for confirmation. Monitor revenue growth catalysts like AVGO's 23.9% or ELV's 12.0% alongside macro trends in housing (LOW) or aerospace (TDG). Dollar-cost average into defensives (KO, JNJ) during volatility; scale into growth (AVGO, TDG) on positive earnings sentiment. Track ROIC trends for conviction, avoiding overexposure to recent laggards like NKE (-13.7% 1Y).
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
How were these stocks selected?
These 10 best stock picks were curated via ValueSense screener focusing on Quality rating above 5.0, strong FCF margins, high ROIC, and intrinsic value upside, spanning diversified sectors for comprehensive value analysis.
What's the best stock from this list?
AVGO leads with an 8.2 Quality rating, 49.8% 1Y Return, and 42.1% FCF margin, though "best" depends on risk tolerance—defensives like KO (33.7% ROIC) suit conservatives.
Should I buy all these stocks or diversify?
Diversification across sectors (tech, healthcare, staples) reduces risk; allocate based on conviction in metrics like ELV's 12.0% growth vs. AVGO's scale, using ValueSense for custom watchlists.
What are the biggest risks with these picks?
Key concerns include debt levels (KO 142.5%), revenue slowdowns (NKE -5.0%), and sector cycles (LOW housing exposure); balance with net cash names like SBUX and TDG.
When is the best time to invest in these stocks?
Target dips to intrinsic value (e.g., JNJ $196.8), positive revenue catalysts, or market corrections; use ValueSense backtesting for timing aligned with historical ROIC trends.